Product
Cyclophosphamide + Fludarabine
5 clinical trials
19 indications
Indication
Solid TumorIndication
Autoimmune DiseasesIndication
Neuromyelitis Optica Spectrum DisorderIndication
Myasthenia GravisIndication
Idiopathic Inflammatory MyopathiesIndication
Multiple SclerosisIndication
autoimmune encephalitisIndication
MOGADIndication
POEMS syndromeIndication
Diffuse Intrinsic Pontine GliomaIndication
Brainstem GliomaIndication
Non-Hodgkin's Lymphomas, B-CellIndication
Diffuse Large B-cell LymphomaIndication
Primary Mediastinal B-cell LymphomaIndication
Transformed Follicular LymphomaIndication
Follicular LymphomaIndication
Mantle Cell LymphomaClinical trial
A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid TumorsStatus: Recruiting, Estimated PCD: 2026-06-28
Clinical trial
An Open Label Clinical Trial to Evaluate the Safety and Efficacy of CT103A Cells for the Treatment of Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous SystemStatus: Recruiting, Estimated PCD: 2027-02-22
Clinical trial
BRAVO: Newly-Diagnosed Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Recovery From Focal Radiotherapy Alone or Focal Radiotherapy and Dose-intensified Temozolomide (Phase I)Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Phase 1, Open-Label, Single Center Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Participants With Treatment Refractory Progressive Multiple SclerosisStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Phase I Dose Escalation Trial of Autologous Third-generation Anti-CD19 Chimeric Antigen Receptor T-cells (WZTL-002) for Relapsed and Refractory B-cell LymphomasStatus: Recruiting, Estimated PCD: 2024-05-01